S-ClassAbout S-Class
Q
QGENAI Stock Diagnostic Report
Qiagen jumps on report EQT in advanced talks to purchase the testing firm
Private equity firm EQT proposed an offer of more than $50 per share for its acquisition of Qiagen, causing QGEN's stock price to rise.
View Source Article ↗AI CATALYST SCORE82 / 100Score computed by Sentinel V12
REFERENCE PRICE$49.51Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support41.94
Near-Term Resistance47.28
02
FUNDAMENTALS
Financial & Fundamental Analysis
The private fund EQT AB's acquisition proposal for over $50 reflects an immediate premium on the current price ($49.51) and acts as a factor supporting short-term downward pressure.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current stock price has broken above the 20-day high-point resistance line ($47.28) and is trading, so short-term overheating must be monitored.
Support41.94
Resistance47.28
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The reported takeover push by EQT on European molecular diagnostics company QIAGEN has significantly improved investor sentiment.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-10-20)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.